Herpes Simplex Virus (HSV)-associated oncolytic virus therapeutics are a promising approach to cancer treatment. These treatments use genetically engineered HSV to target and destroy cancer cells while preserving healthy tissue specifically. The HSV is designed to increase selectively within tumor cells, causing their demise via viral lysis. Furthermore, these modified viruses can be programmed to express therapeutic genes that boost the immune response to the tumor. This combination action—direct oncolysis and immune system stimulation—forms a potent method for attacking cancer. Clinical trials have demonstrated that HSV-based oncolytic virus therapy can improve trea...
